KYMR•benzinga•
JP Morgan Maintains Overweight on Kymera Therapeutics, Raises Price Target to $64
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga